Wellington Management Group LLP Has $1.15 Million Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Wellington Management Group LLP trimmed its holdings in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 67.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 235,123 shares of the company's stock after selling 478,277 shares during the period. Wellington Management Group LLP owned 0.54% of Kyverna Therapeutics worth $1,150,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of KYTX. Novo Holdings A S raised its holdings in shares of Kyverna Therapeutics by 150.0% in the second quarter. Novo Holdings A S now owns 1,750,000 shares of the company's stock valued at $13,125,000 after buying an additional 1,050,000 shares during the last quarter. Deerfield Management Company L.P. Series C increased its position in Kyverna Therapeutics by 35.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,983,000 shares of the company's stock valued at $14,872,000 after acquiring an additional 520,663 shares in the last quarter. MBB Public Markets I LLC bought a new position in shares of Kyverna Therapeutics in the second quarter worth about $3,076,000. Great Point Partners LLC lifted its position in shares of Kyverna Therapeutics by 232.8% during the second quarter. Great Point Partners LLC now owns 499,152 shares of the company's stock worth $3,744,000 after purchasing an additional 349,152 shares in the last quarter. Finally, Millennium Management LLC grew its stake in shares of Kyverna Therapeutics by 32.8% during the second quarter. Millennium Management LLC now owns 923,082 shares of the company's stock valued at $6,923,000 after purchasing an additional 227,988 shares during the last quarter. Institutional investors own 18.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on KYTX. Wells Fargo & Company decreased their price objective on Kyverna Therapeutics from $44.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, November 15th. UBS Group assumed coverage on shares of Kyverna Therapeutics in a research report on Thursday, October 10th. They set a "buy" rating and a $13.00 target price on the stock. Rodman & Renshaw initiated coverage on shares of Kyverna Therapeutics in a research report on Wednesday, October 9th. They set a "buy" rating and a $16.00 price target for the company. HC Wainwright cut their price objective on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a "neutral" rating on the stock in a report on Wednesday, November 20th. Finally, RODMAN&RENSHAW raised shares of Kyverna Therapeutics to a "strong-buy" rating in a report on Wednesday, October 9th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $25.71.

Kyverna Therapeutics Trading Up 3.4 %

KYTX traded up $0.13 during mid-day trading on Friday, hitting $4.00. The stock had a trading volume of 1,404,265 shares, compared to its average volume of 455,397. The stock's fifty day simple moving average is $4.96 and its 200-day simple moving average is $6.96. Kyverna Therapeutics, Inc. has a 1-year low of $3.63 and a 1-year high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last posted its earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.01. The business had revenue of $0.01 million for the quarter. Equities research analysts anticipate that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current year.

Kyverna Therapeutics Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.